{"id":812695,"date":"2025-02-13T08:03:19","date_gmt":"2025-02-13T13:03:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\/"},"modified":"2025-02-13T08:03:19","modified_gmt":"2025-02-13T13:03:19","slug":"silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\/","title":{"rendered":"Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\">\nSilence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025<\/p>\n<p>LONDON&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nSilence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025.<\/p>\n<p>\nManagement will host a conference call at 8:00 a.m. ET \/ 1:00 p.m. GMT that day to discuss the Company\u2019s financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.silence-therapeutics.com&amp;esheet=54204448&amp;newsitemid=20250213336305&amp;lan=en-US&amp;anchor=www.silence-therapeutics.com&amp;index=1&amp;md5=6ca80766cbf9d5392e58398512abf98a\">www.silence-therapeutics.com<\/a>. The webcast will also be archived on the Company\u2019s website.<\/p>\n<p><b>Details of the webcast and conference call:<\/b><\/p>\n<p><b>Webcast link: <\/b><b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.media-server.com%2Fmmc%2Fp%2F73gzxc8m&amp;esheet=54204448&amp;newsitemid=20250213336305&amp;lan=en-US&amp;anchor=https%3A%2F%2Fedge.media-server.com%2Fmmc%2Fp%2F73gzxc8m&amp;index=2&amp;md5=de7fc63b6b821b049b76914d22b52df6\">https:\/\/edge.media-server.com\/mmc\/p\/73gzxc8m<\/a><\/b><\/p>\n<p><b>Conference call registration link:<\/b><b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fregister.vevent.com%2Fregister%2FBIbb8ec3d3557e47e3a4db7b8c03339124&amp;esheet=54204448&amp;newsitemid=20250213336305&amp;lan=en-US&amp;anchor=https%3A%2F%2Fregister.vevent.com%2Fregister%2FBIbb8ec3d3557e47e3a4db7b8c03339124&amp;index=3&amp;md5=23f958f59799947ecf0cc8a05e2787ba\">https:\/\/register.vevent.com\/register\/BIbb8ec3d3557e47e3a4db7b8c03339124<\/a><\/b><\/p>\n<p><b>About Silence Therapeutics<br \/>\n<br \/><\/b>Silence Therapeutics is a global clinical stage biotechnology company committed to transforming people\u2019s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD\u2122 platform to create innovative siRNAs designed to precisely target and silence disease associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.silence-therapeutics.com%2F&amp;esheet=54204448&amp;newsitemid=20250213336305&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.silence-therapeutics.com%2F&amp;index=4&amp;md5=ceeee7bf24a9d02d4f498082cb39069a\">https:\/\/www.silence-therapeutics.com\/<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250213336305r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250213336305\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250213336305\/en\/<\/a><\/span><\/p>\n<p><b>Inquiries:<\/b><\/p>\n<p><b>Silence Therapeutics plc<br \/>\n<\/b><br \/>Gem Hopkins, VP, Head of IR and Corporate Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@silence-therapeutics.com\">ir@silence-therapeutics.com<br \/>\n<\/a><br \/>Tel: +1 (646) 637-3208<\/p>\n<p><b>KEYWORDS:<\/b> United Kingdom Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Genetics Pharmaceutical Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250213336305\/en\/2379294\/3\/Silence-Logo-FINAL-rgb.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 LONDON&#8211;(BUSINESS WIRE)&#8211; Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025. Management will host a conference call at 8:00 a.m. ET \/ 1:00 p.m. GMT that day to discuss the Company\u2019s financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com. The webcast will also be archived on the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-812695","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 LONDON&#8211;(BUSINESS WIRE)&#8211; Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025. Management will host a conference call at 8:00 a.m. ET \/ 1:00 p.m. GMT that day to discuss the Company\u2019s financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com. The webcast will also be archived on the &hellip; Continue reading &quot;Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-13T13:03:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250213336305r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025\",\"datePublished\":\"2025-02-13T13:03:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\\\/\"},\"wordCount\":300,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250213336305r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\\\/\",\"name\":\"Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250213336305r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-02-13T13:03:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250213336305r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250213336305r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\/","og_locale":"en_US","og_type":"article","og_title":"Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 - Market Newsdesk","og_description":"Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 LONDON&#8211;(BUSINESS WIRE)&#8211; Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025. Management will host a conference call at 8:00 a.m. ET \/ 1:00 p.m. GMT that day to discuss the Company\u2019s financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com. The webcast will also be archived on the &hellip; Continue reading \"Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-13T13:03:19+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250213336305r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025","datePublished":"2025-02-13T13:03:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\/"},"wordCount":300,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250213336305r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\/","name":"Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250213336305r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-02-13T13:03:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250213336305r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250213336305r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-to-report-fourth-quarter-and-full-year-2024-results-on-february-27-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/812695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=812695"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/812695\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=812695"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=812695"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=812695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}